BIBLIOGRAFÍA

1. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499-516.
2. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458-65.
3. Shaw B, Cheater F, Baker R, Gillies C, Hearnshaw H, Flottorp S, et al. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2005(3):CD005470. .
4. Evaluación de guías de práctica clínica: Instrumento AGREE [documento internet]. Osteba: Departamento de Sanidad del Gobierno Vasco; 2001 [acceso 20 de septiembre de 2011]. Disponible en: http://www.agreecollaboration.org/pdf/es.pdf.
5. CEBM Centre for Evidence Based Medicine [homepage]. Levels of Evidence 2001. Oxford: University of Oxford; 2011 [actualizada el 16 de septiembre de 2011 16 september 2011; acceso 14 de noviembre de 2011 ]; Disponible en:Available from: http://www.cebm.net/index.aspx?o=1025.
6. Taylor WJ, Grainger R. Clinical features of gout. En: Terkeltaub R, editor. Gout and other crystal arthropathies. 1st edition ed. Philadelphia, USA: Elsevier Saunders; 2011. p. 105-20.
7. Zhu Y, Pandya B, Choi H. Prevalence of gout and hyperuricemia in the adult US population: NHANES 2007-2008. Arthritis Rheum. 2011;63(10).
8. De Miguel E, Puig JG, Castillo C, Peiteado D, Torres RJ, Martin-Mola E. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis. 2012 Jan;71(1):157-8.
9. Rouault T, Caldwell DS, Holmes EW. Aspiration of the asymptomatic metatarsophalangeal joint in gout patients and hyperuricemic controls. Arthritis Rheum. 1984;25(2):209-12.
10. Puig JG, de Miguel E, Castillo MC, Rocha AL, Martinez MA, Torres RJ. Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):592-5.
11. Gibson T. Hyperuricemia, gout and the kidney. Curr Opin in Rheumatolo. 2012;24(2):127-31..
12. Smith EU, Diaz-Torne C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010;24(6):811-27..
13. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HRJ, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis. 2005;64:267-72.
14. Cea Soriano L, Rothenbacher D, Choi HK, Garcia Rodriguez LA. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2011;13(2):R39..
15. Harrold LR, Saag K, Yood RA, Mikuls TR, Andrade SE, Fouayzi H, et al. Validity of gout diagnoses in administrative data. Arthritis Rheum. 2007;57 (1):103-8.
16. Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29(11):2403-6..
17. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3(8):443-9..
18. Macarrón P, Blanco M, Abásolo L, Lajas C, Carmona L, Jover J. Incapacidad laboral producida por gota: descripcion y resultados de un programa de intervencion especifico. Rev Esp Reumatol. 2004;31(2):109.
19. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology. Rheumatology (Oxford). 2007 Sep;46(9):1441-4.
20. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health related quality of life and higher health care utilization in US veterans. 2008 Sep;67(9):1310-6.
21. Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009 Feb;15(1):3-7.
22. Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009;48(5):582-6.
23. Singh JA. Quality of life and quality of care for patients with gout. Curr Rheumatol Rep. 2009;11(2):154-60.
24. Singh JA. Health care costs in Gout. What are these emerging data telling us?. J Clin Rheumatol. 2009;15(1):1-2.
25. Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10-5.
26. Hanly JG, Skedgel C, Sketris I, Cooke C, Linehan T, Thompson K, et al. Gout in the elderly–a population health study. J Rheumatol. 2009;36(4):822-30.
27. Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M. Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy. Am J Ther. 2012 Nov;19(6):e157-66.
28. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2007;67:960-6.
29. Lawrence RG, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum. 2008;58(1):26-35.
30. Anagnostopoulos I, Zinzaras E, Alexiou I, Papathanasiou AA, Davas E, Koutroumpas A, et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord. 2010;11:98.
31. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-41.
32. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;52(1):283-9.
33. Li S, Micheletti R. Role of diet in rheumatic disease. Rheum Dis Clin North Am. 2011;37(1):119-33.
34. Gaffo AL, Roseman JM, Jacobs DR, Jr., Lewis CE, Shikany JM, Mikuls TR, et al. Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Ann Rheum Dis. 2010 Nov;69(11):1965-70.
35. Choi HK, Curhan G. Alcohol and gout. Am J Med. 2007;120(10):e5.
36. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363(9417):1277-81.
37. Choi HK, Curham C. Beer, liquor, and wine consumption and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2004;51(6):1023-9.
38. Jacob RA, Spinozzi GM, Simon VA, Kelley DS, Prior RL, Hess-Pierce B, et al. Consumption of cherries lowers plasma urate in healthy women. J Nutr. 2003;133(6):1826-9.
39. Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11(2):R46.
40. Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Schneider KA, et al. Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med. 1987;147(4):645-9.
41. Wang WH, Chang SJ, Wang TN, Cheng LS, Feng YP, Chen CJ, et al. Complex segregation and linkage analysis of familial gout in Taiwanese aborigines. Arthritis Rheum. 2004;50(1):242-6.
42. Gao X, Curhan G, Forman JP, Ascherio A, Choi HK. Vitamin C intake and serum uric acid concentration in men. J Rheumatol. 2008 Sep;35(9):1853-8 .
43. Burack DA, Griffith BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med. 1992;92(2):141-6.
44. Clive DM. Renal-transplant associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11:974-9.
45. Hernandez-Molina G, Cachafeiro-Vilar A, Villa AR, Alberu J, Rull-Gabayet M. Gout in Renal Allograft Recipients According to the Pretransplant Hyperuricemic Status. Transplantation. 2009;86:1543-7.
46. West C, Carpenter BJ, Hakala TR. The incidence of gout in renal transplant recipients. Am J Kidney Dis. 1987;10(5):369-72.
47. Stamp L, Searle M, OïDonell J, Chapman P. Gout in solid organ transplantation. A challenging clinical problem. Drugs. 2005;65(18):2593-611.
48. Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum. 2007;57(5):816-21.
49. Choi HK, Willet W, Curhan G. Coffee Consumption and Risk of Incident Gout in Men A Prospective Study. Arthritis Rheum. 2007;56 (6 ):2049-55.
50. Caulfield MJ, Munroe PB, O’Neill D, Witkowska K, Charchar FJ, Doblado M, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5(10):e197.
51. Huang CM, Lo SF, Lin HC, Chen ML, Tsai CH, Tsai FJ. Correlation of oestrogen receptor gene polymorphism with gouty arthritis. Ann Rheum Dis. 2006;65(12):1673-4.
52. Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet. 2008;83(6):744-51.
53. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoSGenet. 2009;5(6):e1000504.
54. Hjortnaes J, Algra A, Olijhoek J, Huisman M, Jacobs J, van der Graaf Y, et al. Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. J Rheumatol. 2007;34(9):1882-7.
55. Hernandez-Cuevas CB, Roque LH, Huerta-Sil G, Rojas-Serrano J, Escudero A, Perez LL. First acute gout attacks commonly precede features of the metabolic syndrome. J Rheumatol. 2009;15(2):65-7.
56. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15.
57. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord. 1996;20(11):975-80.
58. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27(6):1501-5.
59. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. ArchIntern Med. 2005;165(7):742-8.
60. Perstein TS, Gumeniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, et al. Uric acid and the development of hypertension: the Normative Aging Study. Hypertension. 2006;48:1031-6.
61. Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, Wagenknecht LE, et al. Serum Uric Acid Predicts Incident Hypertension in a Biethnic Cohort. The Atherosclerosis Risk in Communities Study. Hypertension. 2006 Dec;48(6):1037-42.
62. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49(2):298-303.
63. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61(2):225-32.
64. Hieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux SE, de Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Intern. 2004;65:1041-9.
65. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. ArchInternMed. 2008;168(10):1104-10.
66. Niskanen LK, Laaksonen DE, Nyyssonnen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric Acid Level as a Risk Factor for Cardiovascular and All-Cause Mortality in Middle-aged Men. A Prospective Cohort Study. Arch Intern Med. 2004;164:1546-51.
67. Perry ME, Sturrock RD. Gout is a risk factor for cardiovascular disease. Practitioner. 2007;251(1701):25-8.
68. Puig JG, Martinez MA, Mora M, Fraile JM, Montoya F, Torres RJ. Serum urate, metabolic syndrome, and cardiovascular risk factors. A population-based study. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):620-3.
69. Shah A, Keenan RT. Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep. 2010;12(2):118-24.
70. McCarty DJ. A historical note: Leeuwenhoek’s description of crystals from a gouty tophus. Arthritis Rheum. 1970;13(4):414-8.
71. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452-60.
72. Pascual Gomez E. [Diagnosis of gout]. Med Clin (Barc). 2004;123(20):798.
73. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1301-11.
74. Doherty M, Bardin T, Pascual E. International survey on the diagnosis and management of gout. Annals of the rheumatic diseases. 2007;66(12):1685-6.
75. Perez-Ruiz F, Carmona L, Yebenes MJ, Pascual E, de Miguel E, Urena I, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011;17(7):349-55.
76. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis. 2007;66(10):1311-5.
77. Wolfe F, Cathey MA. The misdiagnosis of gout and hyperuricemia. J Rheumatol. 1991;18(8):1232-4.
78. Hamburger M, Baraf HS, Adamson TC, 3rd, Basile J, Bass L, Cole B, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(6 Suppl 1):3-36.
79. Phelps P, Steele AD, McCarty DJ, Jr. Compensated polarized light microscopy. Identification of crystals in synovial fluids from gout and pseudogout. JAMA. 1968;203(7):508-12.
80. Sivera F, Aragon R, Pascual E. First metatarsophalangeal joint aspiration using a 29-gauge needle. Ann RheumdDis. 2008;67(2):273-5.
81. McCarty DJ. Crystal identification in human synovial fluids. Methods and interpretation. Rheum Dis Clin North Am. 1988;14(2):253-67.
82. Galvez J, Saiz E, Linares LF, Climent A, Marras C, Pina MF, et al. Delayed examination of synovial fluid by ordinary and polarised light microscopy to detect and identify crystals. Ann Rheumatic Dis. 2002;61(5):444-7.
83. Schumacher HR, Reginato AJ. Atlas of synovial fluid analysis and crystal identification. Philadelphia: Lea & Febiger; 1991.
84. Pascual E, Tovar J, Ruiz MT. The ordinary light microscope: an appropriate tool for provisional detection and identification of crystals in synovial fluid. Ann Rheum Dise. 1989;48(12):983-5.
85. Pascual E, Sivera F, Andres M. Synovial fluid analysis for crystals. Curr Opin Rheumatol. 2011;23(2):161-9.
86. Bomalaski JS, Lluberas G, Schumacher HR, Jr. Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum. 1986;29(12):1480-4.
87. Gordon TP, Bertouch JV, Walsh BR, Brooks PM. Monosodium urate crystals in asymptomatic knee joints. J Rheumatol. 1982;9(6):967-9.
88. Kennedy TD, Higgens CS, Woodrow DF, Scott JT. Crystal deposition in the knee and great toe joints of asymptomatic gout patients. J R Soc Med. 1984;77(9):747-50.
89. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum. 1991;34(2):141-5.
90. Pascual E, Batlle-Gualda E, Martinez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med. 1999;131(10):756-9. Epub 1999/11/30.
91. Rouault T, Caldwell DS, Holmes EW. Aspiration of the asymptomatic metatarsophalangeal joint in gout patients and hyperuricemic controls. Arthritis Rheum. 1982;25(2):209-12.
92. Weinberger A, Schumacher HR, Agudelo CA. Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med. 1979;91(1):56-7. Epub 1979/07/01.
93. Romanoff NR, Canoso JJ, Rubinow A, Spark EC. Gout without crystals on initial synovial fluid analysis. Postgrad Med J. 1978;54(628):95-7.
94. Schumacher HR, Jimenez SA, Gibson T, Pascual E, Traycoff RB, Dorwart BB, et al. Acute gouty arthritis without urate crystals identified on initial examination of synovial fluid. Report of nine patients. Arthritis Rheum 1975;18:603-12.
95. Hasselbacher P. Variation in synovial fluid analysis by hospital laboratories. Arthritis Rheum. 1987;30(6):637-42.
96. Schumacher HR, Jr., Sieck MS, Rothfuss S, Clayburne GM, Baumgarten DF, Mochan BS, et al. Reproducibility of synovial fluid analyses. A study among four laboratories. Arthritis Rheum. 1986;29(6):770-4.
97. Von Essen R, Holtta AM. Quality control of the laboratory diagnosis of gout by synovial fluid microscopy. Scand J Rheumatol. 1990;19(3):232-4.
98. von Essen R, Holtta AM, Pikkarainen R. Quality control of synovial fluid crystal identification. AnnRheumDis. 1998;57(2):107-9.
99. Lumbreras B, Pascual E, Frasquet J, Gonzalez-Salinas J, Rodriguez E, Hernandez-Aguado I. Analysis for crystals in synovial fluid: training of the analysts results in high consistency. AnnRheum Dis. 2005;64(4):612-5.
100. Shah K, Spear J, Nathanson LA, McCauley J, Edlow JA. Does the presence of crystal arthritis rule out septic arthritis? J Emerg Med. 2007;32(1):23-6.
101. Yu KH, Luo SF, Liou LB, Wu YJ, Tsai WP, Chen JY, et al. Concomitant septic and gouty arthritis–an analysis of 30 cases. Rheumatology (Oxford). 2003;42(9):1062-6.
102. Bennett PH, Wood PHN, National Institute of Arthritis and Metabolic Diseases (U.S.), editors. Population studies of the rheumatic diseases; proceedings of the third international symposium, New York, June 5th-10th, 1966, sponsored by the National Institute of Arthritis and Metabolic Diseases and the Arthritis Foundation. Edited byPeter H. Bennett and Philip H. N. Wood.; Amsterdam; New York [etc.]: Excerpta Medica Foundation [1968].
103. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895-900.
104. Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170(13):1120-6.
105. Pelaez-Ballestas I, Hernandez Cuevas C, Burgos-Vargas R, Hernandez Roque L, Teran L, Espinoza J, et al. Diagnosis of chronic gout: evaluating the american college of rheumatology proposal, European league against rheumatism recommendations, and clinical judgment. J Rheumatol. 2010;37(8):1743-8.
106. Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol.2009;15(1):22-4.
107. Johnson SR, Goek ON, Singh-Grewal D, Vlad SC, Feldman BM, Felson DT, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007;57(7):1119-33.
108. Janssens HJ, Janssen M, van de Lisdonk EH, Fransen J, van Riel PL, van Weel C. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. AnnRheum Dise. 2010;69(6):1255-6.
109. Vazquez-Mellado J, Hernandez-Cuevas CB, Alvarez-Hernandez E, Ventura-Rios L, Pelaez-Ballestas I, Casasola-Vargas J, et al. The diagnostic value of the proposal for clinical gout diagnosis (CGD). Clin Rheumatol. 2012;31(3):429-34.
110. Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. AnnRheum Dise. 1983;42 Suppl 1:12-5.
111. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82(3):421-6..
112. Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout. Ann Rheum Dis. 1997;56(11):696-7.
113. Schlesinger N, Baker DG, Schumacher HR, Jr. Serum urate during bouts of acute gouty arthritis. J Rheumatol. 1997;24(11):2265-6.
114. Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol. 2009;36(6):1287-9.
115. Urano W, Yamanaka H, Tsutani H, Nakajima H, Matsuda Y, Taniguchi A, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002;29(9):1950-3.
116. Perez Ruiz F, Ruiz Lopez J, Herrero Beites AM. Influencia de la historia natural de la enfermedad en el diagnostico previo en pacientes con gota. Reumatol Clin. 2009;5(6):248-51.
117. Schlesinger N. Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides. J Clin Rheumatol.. 2006;12(6):275-6.
118. Fiechtner JJ, Simkin PA. Urate spherulites in gouty synovia. JAMA. 1981;245(15):1533-6.
119. Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol. 2007;34(9):1888-93.
120. Perez-Ruiz F, Urresola A, Gorostiza D, Canteli B. Validation of the measuremente of tophi with magnetic resonance imaging as an outcome meaure for chronic gout. Arthritis Rheum. 2011;63 (Suppl 10):S77.
121. Brower AC. Gout. In: Brower AC, Flemming DJ, editors. Arthritis in black and white. 2 ed. Philadelphia: W.B. Saunders; 1997. p. 325-41.
122. Wright SA, Filippucci E, McVeigh C, Grey A, McCarron M, Grassi W, et al. High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study. AnnRheum Dis. 2007;66(7):859-64.
123. McCarthy GM, Barthelemy CR, Veum JA, Wortmann RL. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum. 1991;34(12):1489-94.
124. Yu T, Gutman AB. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med. 1967;67(6):1133-48.
125. Dalbeth N, Clark B, Gregory K, Gamble G, Sheehan T, Doyle A, et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. AnnRheum Dis. 2009;68(8):1290-5.
126. Perez-Ruiz F, Dalbeth N, Urresola A, de Miguel E, Schlesinger N. Imaging of gout: findings and utility. Arthritis Res Ther. 2009;11(3):232.
127. Dalbeth N, Clark B, McQueen F, Doyle A, Taylor W. Validation of a radiographic damage index in chronic gout. Arthritis Rheum. 2007;57(6):1067-73.
128. Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford). 2007;46(12):1804-7.
129. Chen CK, Chung CB, Yeh L, Pan HB, Yang CF, Lai PH, et al. Carpal tunnel syndrome caused by tophaceous gout: CT and MR imaging features in 20 patients. AJR Am J Roentgenol. 2000;175(3):655-9.
130. Dalbeth N, Schauer C, Macdonald P, Perez-Ruiz F, Schumacher HR, Hamburger S, et al. Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. AnnRheumDis. 2011;70(4):597-604.
131. Desai MA, Peterson JJ, Garner HW, Kransdorf MJ. Clinical utility of dual-energy CT for evaluation of tophaceous gout. Radiographics. 2011;31(5):1365-75; discussion 76-7.
132. Glazebrook KN, Guimaraes LS, Murthy NS, Black DF, Bongartz T, N JM, et al. Identification of Intraarticular and Periarticular Uric Acid Crystals with Dual-Energy CT: Initial Evaluation. Radiology. 2011;261(2):516-24.
133. Nicolaou S, Yong-Hing CJ, Galea-Soler S, Hou DJ, Louis L, Munk P. Dual-energy CT as a potential new diagnostic tool in the management of gout in the acute setting. AJR Am J Roentgenol. 2010;194(4):1072-8.
134. Glazebrook KN, Kakar S, Ida CM, Laurini JA, Moder KG, Leng S. False-negative dual-energy computed tomography in a patient with acute gout. J Clin Rheumatol.2012;18(3):138-41.
135. Yu JS, Chung C, Recht M, Dailiana T, Jurdi R. MR imaging of tophaceous gout. AJR Am J Roentgenol. 1997;168(2):523-7.
136. Popp JD, Bidgood WD, Jr., Edwards NL. Magnetic resonance imaging of tophaceous gout in the hands and wrists.Semin Arthritis Rheum. 1996;25(4):282-9.
137. Schumacher HR, Jr., Becker MA, Edwards NL, Palmer WE, MacDonald PA, Palo W, et al. Magnetic resonance imaging in the quantitative assessment of gouty tophi. Int J Clin Pract. 2006;60(4):408-14.
138. Resnick D. Crystal induced and related diseases. Diagnosis of bone and joint disorders Philadelphia: Saunders Co; 1995. p. 1511-51.
139. Dalbeth N, Doyle A, Boyer L, Rome K, Survepalli D, Sanders A, et al. Development of a computed tomography method of scoring bone erosion in patients with gout: validation and clinical implications. Rheumatology (Oxford). 2011;50(2):410-6.
140. Stewart RE, Vroegop S, Kamps GB, van der Werf GT, Meyboom-de Jong B. Factors influencing adherence to guidelines in general practice. Int J Technol Assess Health Care. 2003;19(3):546-54.
141. Malik A, Schumach H, Dinnella J, Clayburne G, Mer H, Dinnella J, et al. Validation of gout clinical diagnostic criteria in VA patients compared with the gold standard of synovial fluid crystal analysis. Arthritis Rheum. 2007;56:S(639)-40.
142. de Miguel E. Papel de la ecografia en las artritis microcristalinas [Role of ultrasound in microcrystalline arthritis]. Reumatol Clin. 2008;4S2:50-4.
143. Grassi W, Meenagh G, Pascual E, Filippucci E. “Crystal clear”-sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin Arthritis Rheum . 2006;36(3):197-202.
144. Peiteado D, De Miguel E, Villalba A, Ordoñez M, Castillo C, Martín-Mola E. Value of a short four-joint ultrasound test for gout diagnosis:A pilot study. Clin Exp Rheumatol. 2012 Nov-Dec;30(6):830-7.
145. Rettenbacher T, Ennemoser S, Weirich H, Ulmer H, Hartig F, Klotz W, et al. Diagnostic imaging of gout: comparison of high-resolution US versus conventional X-ray. Eur Radiol. 2008;18(3):621-30.
146. Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheumatology (Oxford). 2007;46(7):1116-21.
147. Filippucci E, Riveros MG, Georgescu D, Salaffi F, Grassi W. Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study. Osteoarthritis Cartilage. 2009;17(2):178-81.
148. De Miguel E, Puig JG, Castillo C, Peiteado D, Torres RJ, Martin-Mola E. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis. 2012 Jan;71(1):157-8.
149. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis.2006;65(10):1312-24.
150. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford). 2009;48 Suppl 2:ii9-ii14.
151. Oliver JE, Silman AJ. What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases. Arthritis Res Ther. 2009;11(3):223.
152. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46(8):1372-4.
153. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010;49(1):141-6.
154. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323(7304):75-81.
155. Buitrago Ramirez F, Canon Barroso L, Diaz Herrera N, Cruces Muro E, Bravo Simon B, Perez Sanchez I. Comparacion entre la tabla del SCORE y la funcion Framingham-REGICOR en la estimacion del riesgo cardiovascular en una poblacion urbana seguida durante 10.. Med Clin (Barc). 2006;127(10):368-73.
156. Buitrago F, Canon Barroso L, Diaz Herrera N, Cruces E. Analisis de la capacidad predictiva de las funciones de Framingham-REGICOR y SCORE en la poblacion de un centro de salud. Med Clin (Barc). 2007;129(20):797.
157. Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. C Calibracion de la tabla SCORE de riesgo cardiovascular para Espana Rev Esp Cardiol. 2007;60(5):476-85.
158. Bennett M. A Risk Score Calculator for Cardiovascular Disease. Disponible en:: http://riskscore.lshtm.ac.uk/calculator.html.
159. World Health Organization. Definition, diagnosis and classification of Diabetes Mellitus and its complications. 1999. Disponible en: http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf.
160. Grundy SM, Hansen B, Smith SC, Jr., Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol. 2004;24(2):e19-24.
161. Schumacher HR, Jr., Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, et al. Outcome measures for acute and chronic gout. J Rheumatol. 2005;32(12):2452-5.
162. Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N, et al. Outcome evaluations in gout. J Rheumatol. 2007;34(6):1381-5.
163. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol. 2009;36(10):2342-5.
164. Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, et al. Progress in measurement instruments for acute and chronic gout studies. J Rheumatol. 2009;36(10):2346-55.
165. Esteve-Vives J, Batlle-Gualda E, Reig A. Spanish version of the Health Assessment Questionnaire: reliability, validity and transcultural equivalency. J Rheumatol. 1993;20(12):2116-22.
166. Gawlicki MC, Reilly MC, Popielnicki A, Reilly K. Linguistic validation of the US Spanish work productivity and activity impairment questionnaire, general health version. Value Health. 2006;9(3):199-204.
167. Stamp LK, Khanna PP, Dalbeth N, Boers M, Maksymowych WP, Schumacher HR, Jr., et al. Serum urate in chronic gout–will it be the first validated soluble biomarker in rheumatology? J Rheumatol. 2011;38(7):1462-6.
168. Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, et al. Developing a provisional definition of a flare in patients with established gout. Arthritis Rheum. 2012 May;64(5):1508-17
169. Hirsch JD, Lee SJ, Terkeltaub R, Khanna D, Singh J, Sarkin A, et al. Evaluation of an instrument assessing influence of Gout on health-related quality of life. J Rheumatol. 2008;35(12):2406-14.
170. Pascual E, Jovani V. Synovial fluid analysis. Best Pract Res Clin Rheumatol. 2005;19(3):371-86.
171. Kuo CF, Yu KH, Luo SF, Chiu CT, Ko YS, Hwang JS, et al. Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol. 2010;39(6):466-71.
172. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008;47(10):1567-70.
173. Hernandez-Cuevas CB, Roque LH, Huerta-Sil G, Rojas-Serrano J, Escudero A, Perez LL, et al. First acute gout attacks commonly precede features of the metabolic syndrome. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2009;15(2):65-7.
174. Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E. Chronic kidney disease in gout in a managed care setting. BMC Nephrol. 2011;12:36. Epub 2011/08/05.
175. Liebman SE, Taylor JG, Bushinsky DA. Uric acid nephrolithiasis. Curr Rheumatol Rep. 2007;9(3):251-7.
176. Fesler P, Mimran A. Estimation of glomerular filtration rate: what are the pitfalls? Curr Hypertens Rep. 2011;13(2):116-21.
177. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002;47(6):610-3.
178. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003;349(17):1647-55.
179. Comité de Seguridad de Medicamentos de Uso Humano de la Agencia Española del Medicamento. Restricción del uso de benzbromarona (Urinorm®) y suspensión de comercialización de benziodarona (Dilafurane®) y de las asociaciones benzbromarona-alopurinol (Acifugan®, Facilit®). Actual Farmacol Terap. 2004;2(1):43.
180. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9):545-9.
181. Perez-Ruiz F, Hernandez-Baldizon S, Herrero-Beites AM, Gonzalez-Gay MA. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout. Arthritis Care Res (Hoboken). 2010;62(9):1299-305. Epub 2010/05/28.
182. Cohen SD, Kimmel PL, Neff R, Agodoa L, Abbott KC. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol. 2008;19(11):2204-10. Epub 2008/05/30.
183. Cameron JS. Uric acid and the kidney. Proc R Soc Med. 1973;66(9):900-2.
184. Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am. 1990;16(3):539-50.
185. Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol. 2005;25(1):43-9.
186. El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease? Cleve Clin J Med. 2010;77(12):919-28.
187. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(7):885-92.
188. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62(2):170-80.
189. Alvarez-Nemegyei J, Medina-Escobedo M, Villanueva-Jorge S, Vazquez-Mellado J. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? J Rheumatol. 2005;32(11):2189-91.
190. Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009;36(5):1041-8.
191. Wu EQ, Yu AP, Guerin A, et al. The costs of treatment failure gout: a claims-based analysis. Arthritis Rheum. 2009;60(10):S1112.
192. Keenan RT, O’Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124(2):155-63.
193. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis. 1996;28(1 Suppl 1):S56-62.
194. Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis. 2003;42(2):217-28.
195. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S-24S. Epub 1999/07/02.
196. Wali RK, Henrich WL. Recent developments in toxic nephropathy. Curr Opin Nephrol Hypertens. 2002;11(2):155-63.
197. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol. 2000;151(5):488-96.
198. Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45(3):531-9.
199. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med. 1996;156(21):2433-9.
200. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(3):280 e1-7. Epub 2007/03/14.
201. Morris I, Varughese G, Mattingly P. Colchicine in acute gout. BMJ. 2003;327(7426):1275-6.
202. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994;331(25):1675-9.
203. Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med. 2002;22(4):385-7.
204. Ehrenfeld M, Levy M, Margalioth EJ, Eliakim M. The effects of long-term colchicine therapy on male fertility in patients with familial Mediterranean fever. Andrologia. 1986;18(4):420-6.
205. Ben-Chetrit E, Scherrmann JM, Zylber-Katz E, Levy M. Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol. 1994;21(4):710-3.
206. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316(25):1562-8.
207. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060-8.
208. FDA. Information for Healthcare Professionals: New Safety Information for Colchicine (marketed as Colcrys). 2009; Disponible en: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174315.htm.
209. Colchicine: serious interactions. Prescrire Int. 2008;17(96):151-3. Epub 2009/06/06.
210. Vasudevan AR, Uthamalingam S, Kumar S, Tamarin F, Brensilver JM. Colchicine-induced rhabdomyolysis: the whole is greater than the sum of its parts! Am J Med. 2003;115(3):249.
211. Bianchi S, Grimaldi D, Bigazzi R. Statins and lipid-lowering strategies in cardiorenal patients. Contrib Nephrol. 2011;171:143-50.
212. System USRD. Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U.S. Department of Health and Human Services. 2007; Disponible en: http://www.usrds.org/2007/pdf/00_intro_07.pdf.
213. Levine SN, Sanson TH. Treatment of hyperglycaemic hyperosmolar non-ketotic syndrome. Drugs. 1989;38(3):462-72.
214. Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994;21(4):696-9.
215. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol. 1994;21(7):1325-7.
216. Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother. 2001;35(3):365-8.
217. Connell JM, Whitworth JA, Davies DL, Lever AF, Richards AM, Fraser R. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens. 1987;5(4):425-33..
218. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.
219. Tausche AK, Richter K, Grassler A, Hansel S, Roch B, Schroder HE. Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Annals of the rheumatic diseases. 2004;63(10):1351-2.
220. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18(2):264-9.
221. AEMPS. Colchicina. Ficha técnica. 2011; Disponible en: http://www.aemps.gob.es/cima/especialidad.do?metodo=verFichaWordPdf&codigo=33720&formato=pdf&formulario=FICHAS&file=ficha.pdf.
222. Ly J, Gow P, Dalbeth N. Colchicine prescribing and safety monitoring in patients with gout. N Z Med J. 2007;120(1265):U2808.
223. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.
224. Becker MA, Schumacher HR, Jr., Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-61.
225. Schumacher HR, Jr., Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-8.
226. Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386-97.
227. Brest AN, Heider C, Mehbod H, Onesti G. Drug control of diuretic-induced hyperuricemia. JAMA. 1966;195(1):42-4.
228. de Vries A, Frank M, Liberman UA, Sperling O. Allopurinol in the prophylaxis of uric acid stones. Annals of the rheumatic diseases. 1966;25(6 Suppl):691-3. Epub 1966/11/01.
229. Gutman AB, Yu TF. Protracted uricosuric therapy in tophaceous gout. Lancet. 1957;273(7008):1258-60.
230. Nicotero JA, Scheib ET, Martinez R, Rodnan GP, Shapiro AP. Prevention of hyperuricemia by allopurinol in hypertensive patients treated with chlorothiazide. N Engl J Med. 1970;282(3):133-5.
231. Yu TF, Gutman AB. Principles of current management of primary gout. Am J Med Sci. 1967;254(6):893-907.
232. Gibson T, Rodgers V, Potter C, Simmonds HA. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis . 1982;41(1):59-65.
233. Schumacher HR, Jr., Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188-94.
234. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51-9.
235. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27(5):435-40.
236. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7-13.
237. Azar AT, Wahba K, Mohamed AS, Massoud WA. Association between dialysis dose improvement and nutritional status among hemodialysis patients. Am J Nephrol. 2007;27(2):113-9.
238. Fouque D, Laville M, Boissel JP. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev. 2006(2):CD001892.
239. Johnson DW. Dietary protein restriction as a treatment for slowing chronic kidney disease progression: the case against. Nephrology (Carlton). 2006;11(1):58-62.
240. Lentine K, Wrone EM. New insights into protein intake and progression of renal disease. Curr Opin Nephrol Hypertens. 2004;13(3):333-6.
241. Mandayam S, Mitch WE. Dietary protein restriction benefits patients with chronic kidney disease. Nephrology (Carlton). 2006;11(1):53-7.
242. National Kidney Foundation. Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. 2000; Disponible en: http://www.kidney.org/professionals/kdoqi/guidelines_updates/doqi_nut.html
243. McGill NW. Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol. 2000;14(3):445-60.
244. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925-34.
245. Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens. 2002;11(5):475-82.
246. Hanvivadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thai. 2002;85 Suppl 1:S40-7.
247. Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol. 2007;26(9):1459-65.
248. Kumar S, Ng J, Gow P. Benzbromarone therapy in management of refractory gout. N Z Med J. 2005;118(1217):U1528.
249. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study.  J Clin Rheumatol. 1999;5(2):49-55.
250. Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis. 2009;68(6):892-7.
251. Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis . 2009;68(1):51-6.
252. Muller FO, Schall R, Groenewoud G, Hundt HK, van der Merwe JC, van Dyk M. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. Eur J Clin Pharmacol. 1993;44(1):69-72.
253. Yamamoto T, Moriwaki Y, Takahashi S, Suda M, Higashino K. Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol. Ann Rheum Dis . 1991;50(9):631-3.
254. Matzkies F. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia]. Med Klin (Munich). 1992;87(9):460-2.
255. Ohno I, Ichida K, Okabe H, Hikita M, Uetake D, Kimura H, et al. Frequency of gouty arthritis in patients with end-stage renal disease in Japan. Intern Med. 2005;44(7):706-9.
256. Chohan S, Becker MA. Update on emerging urate-lowering therapies. Curr Opin Rheumatol. 2009;21(2):143-9.
257. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643-65.
258. Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens. 2004;13(2):181-9. Epub 2004/06/19.
259. Asplin JR. Uric acid stones. Semin Nephrol. 1996;16(5):412-24.
260. Bilobrov VM, Chugaj AV, Bessarabov VI. Urine pH variation dynamics in healthy individuals and stone formers. Urol Int. 1990;45(6):326-31.
261. Murayama T, Taguchi H. The role of the diurnal variation of urinary pH in determining stone compositions. J Urol. 1993;150(5 Pt 1):1437-9.
262. Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int. 1986;30(3):422-8.
263. Coe FL, Strauss AL, Tembe V, Le Dun S. Uric acid saturation in calcium nephrolithiasis. Kidney Int. 1980;17(5):662-8.
264. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966;64(2):229-58.
265. Yu TF. The effect of allopurinol in primary and secondary gout. Arthritis Rheum. 1965;8(5):905-6.
266. US National Library of Medicine. About DailyMed. FDA information: allopurinol tablet. Available from: http://dailymed.nlm.nih.gov/dailymed/about.cfm.
267. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256(24):3358-63.
268. Emmerson BT. The management of gout. N Engl J Med. 1996;334(7):445-51.
269. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27(3):337-43.
270. Perez-Ruiz F, Hernando I, Villar I, Nolla JM. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. J Clin Rheumatol. 2005;11(3):129-33.
271. Khanna D, Pandya BJ, D’Souza AO, Meissner BL, Kamalakar R, Harikrishnan V. Incidence of Allopurinol Hypersensitivity Syndrome (AHS) Among Renally Impaired Patients [abstract]. Arthritis Rheum. 2009;60 Suppl 10 2034.
272. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47-56.
273. Allopurinol U.S. Prescribing Information Apotex Corp. Weston, FL; 2006.
274. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134-9.
275. Stamp L, Gow P, Sharples K, Raill B. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med. 2000;30(5):567-72.
276. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33(8):1646-50.
277. Silverberg M, Mallela R, Lesse A, Bonner M, Baer A, Li C. Allopurinol Hypersensitivity Reactions: A Case-Control Study of the Role of Renal Dosing [abstract]. Arthritis Rheum. 2009;60 Suppl 10:1106.
278. Stamp LK, O’Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412-21.
279. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Annals of the rheumatic diseases. 2001;60(10):981-3.
280. Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004;23(8-9):1111-6.
281. Whelton A BM, MacDonald P, et al. Gout subjects with hyperuricemia and renal impairment treated with febuxostat or allopurinol for 6 months. 2009;20:F-P01115.
282. Lewis DA, Herrington WG. Contraindications to pharmacologic therapies for gout. Am J Med. 2011;124(10):e15.
283. de Lannoy IA, Mandin RS, Silverman M. Renal secretion of vinblastine, vincristine and colchicine in vivo. J Pharmacol Exp Ther. 1994;268(1):388-95. Epub 1994/01/01.
284. Ifudu O, Tan CC, Dulin AL, Delano BG, Friedman EA. Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. Am J Kidney Dis. 1994;23(3):347-51.
285. Schreiner O, Wandel E, Himmelsbach F, Galle PR, Marker-Hermann E. Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients? Nephrol Dial Transplant. 2000;15(5):644-9.
286. Chandna SM, Farrington K. Residual renal function: considerations on its importance and preservation in dialysis patients. Semin Dial. 2004;17(3):196-201.
287. Bennett WM, Aronoff GR, Morrison G, Golper TA, Pulliam J, Wolfson M, et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis. 1983;3(3):155-93.
288. New Zealand Rheumatology Association. NZRA consensus statement on the use of colchicine in the treatment of gout. 2005; Disponible en: http://www.rheumatology.org.nz/colchicine.htm.
289. Rossi S (editor). Australian Medicines Handbook 2010 (online). Adelaide: Australian Medicines Handbook Pty Ltd; 2010. Disponible en: http://www.amh.net.au.
290. Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50(3):937-43. Epub 2004/03/17.
291. Bismuth C. Biological valuation of extra-corporeal techniques in acute poisoning. Acta Clin Belg Suppl. 1990;13:20-8.
292. Knoben J, Anderson P. Handbook of clinical drug data. 6th ed. Hamilton, Ill.: Drug Intelligence Publications; 1988.
293. Ben-Chetrit E, Backenroth R, Levy M. Colchicine clearance by high-flux polysulfone dialyzers. Arthritis Rheum. 1998;41(4):749-50.
294. Johnson WJ, O’Duffy JD. Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol. Mayo Clin Proc. 1979;54(9):618-20.
295. Aasarod K, Wideroe TE, Flakne SC. A comparison of solute clearance and ultrafiltration volume in peritoneal dialysis with total or fractional (50%) intraperitoneal volume exchange with the same dialysate flow rate. Nephrol Dial Transplant. 1997;12(10):2128-32.
296. Krediet RT, Douma CE, van Olden RW, Ho-dac-Pannekeet MM, Struijk DG. Augmenting solute clearance in peritoneal dialysis. Kidney Int. 1998;54(6):2218-25.
297. Miyahira J, Cieza J. Influencia del flujo de dializado en el aclaramiento de Urea, Creatinina y Ácido Úrico en diálisis peritoneal. Rev méd hered. 1990;1(2):2-7.
298. Nolph KD, Twardowski ZJ, Popovich RP, Rubin J. Equilibration of peritoneal dialysis solutions during long-dwell exchanges. J Lab Clin Med. 1979;93(2):246-56..
299. Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum. 2005;52(1):290-5.
300. Elion GB, Benezra FM, Beardmore TD, Kelley WN. Studies with allopurinol in patients with impaired renal function. Adv Exp Med Biol. 1980;122A:263-7.
301. Gores PF, Fryd DS, Sutherland DE, Najarian JS, Simmons RL. Hyperuricemia after renal transplantation. Am J Surg. 1988;156(5):397-400.
302. Stamp L, Searle M, O’Donnell J, Chapman P. Gout in solid organ transplantation: a challenging clinical problem. Drugs. 2005;65(18):2593-611.
303. Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation. 2005;80(10):1383-91.
304. Baroletti S, Bencivenga GA, Gabardi S. Treating gout in kidney transplant recipients. Prog Transplant. 2004;14(2):143-7.
305. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11(5):974-9.
306. Ruilope LM, Garcia-Puig J. Hyperuricemia and renal function. Curr Hypertens Rep. 2001;3(3):197-202.
307. Harris KP, Jenkins D, Walls J. Nonsteroidal antiinflammatory drugs and cyclosporine. A potentially serious adverse interaction. Transplantation. 1988;46(4):598-9. Epub 1988/10/01.
308. Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6(5 Pt 2):1111-31.
309. Boots JM, van Duijnhoven EM, Christiaans MH, Nieman FH, van Suylen RJ, van Hooff JP. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int. 2001;14(6):370-83.
310. Kanbay M, Akcay A, Huddam B, Usluogullari CA, Arat Z, Ozdemir FN, et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. Transplant Proc. 2005;37(7):3119-20.
311. Shibolet O, Elinav E, Ilan Y, Safadi R, Ashur Y, Eid A, et al. Reduced incidence of hyperuricemia, gout, and renal failure following liver transplantation in comparison to heart transplantation: a long-term follow-up study. Transplantation. 2004;77(10):1576-80.
312. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant. 2002;2(5):436-42.
313. Speeg KV, Maldonado AL, Liaci J, Muirhead D. Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo. Hepatology. 1992;15(5):899-903.
314. Speeg KV, Maldonado AL, Liaci J, Muirhead D. Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo. J Pharmacol Exp Ther. 1992;261(1):50-5.
315. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226-37.
316. Food and Drug Administration. Guidance for industry: drug interaction studies—study design, data analysis, and implications for dosing and labeling. Draft guidance. 2006; Dsiponible en: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
317. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Seminars in arthritis and rheumatism. 1990;19(6):329-36.
318. Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, Zarraga S, Calabozo M, Herrero-Beites AM, et al. Long-term efficacy of hyperuricaemia treatment in renal transplant patients. Nephrol Dial Transplant. 2003;18(3):603-6.
319. Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010;3(1):73-81.
320. Zurcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant. 1994;9(5):548-51.
321. Chanard J, Toupance O, Lavaud S, Hurault de Ligny B, Bernaud C, Moulin B. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant. 2003;18(10):2147-53.
322. Sennesael JJ, Lamote JG, Violet I, Tasse S, Verbeelen DL. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients. Am J Kidney Dis. 1996;27(5):701-8.
323. Pascual E, Sivera F. Therapeutic advances in gout. Curr Opin Rheumatol. 2007;19(2):122-7.
324. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8 Suppl 1:S2.
325. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84(2):191-215.
326. Johnson VD. Promoting behavior change: making healthy choices in wellness and healing choices in illness – use of self-determination theory in nursing practice. Nurs Clin North Am. 2007;42(2):229-41, vi.
327. Rollnick S, Miller WR, Butler C. Motivational interviewing in health care : helping patients change behavior. New York: Guilford Press; 2008.
328. Choi JW, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59(1):109-16.
329. Snaith ML. Gout: diet and uric acid revisited. Lancet. 2001;358(9281):525.
330. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Annals of the rheumatic diseases. 2000;59(7):539-43.
331. Lee SJ, Terkeltaub RA, Kavanaugh A. Recent developments in diet and gout. Curr Opin Rheumatol. 2006;18(2):193-8.
332. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2004;51(6):1023-9.
333. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639):309-12.
334. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum. 2007;56(6):2049-55.
335. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37(6):1503-7.
336. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104-10.
337. Tatli E, Aktoz M, Buyuklu M, Altun A. The relationship between coronary artery disease and uric acid levels in young patients with acute myocardial infarction. Cardiol J. 2008;15(1):21-5.
338. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742-8.
339. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29(7):1350-5.
340. Becker MA, Ruoff GE. What do I need to know about gout? J Fam Pract. 2010;59(6 Suppl):S1-8.
341. Dore RK. The gout diagnosis. Cleve Clin J Med. 2008;75 Suppl 5:S17-21.
342. Burmester G, Lanas A, Biasucci L, Hermann M, Lohmander S, Olivieri I, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Annals of the rheumatic diseases. 2011;70(5):818-22.
343. Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011;12:103.
344. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA. 1991;266(21):3004-7.
345. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65(3):1041-9.
346. Ruilope LM. Antihypertensives in people with gout or asymptomatic hyperuricaemia. BMJ. 2012;344:d7961.
347. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148(4):635-40.
348. Fraile M, García Puig J. Síndrome metabólico, hiperuricemia y gota. Revista Española de Obesidad. 2009;7(2):85-90.
349. Bomback AS, Derebail VK, Shoham DA, Anderson CA, Steffen LM, Rosamond WD, et al. Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. Kidney Int. 2010;77(7):609-16.
350. Jalal DI, Smits G, Johnson RJ, Chonchol M. Increased fructose associates with elevated blood pressure. J Am Soc Nephrol. 2010;21(9):1543-9.
351. Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010;22(2):165-72.
352. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093-103.
353. de Lorgeril M, Salen P. Mediterranean diet in secondary prevention of CHD. Public Health Nutr. 2011;14(12A):2333-7.
354. Bach-Faig A, Berry EM, Lairon D, Reguant J, Trichopoulou A, Dernini S, et al. Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr. 2011;14(12A):2274-84.
355. Mediterránea FD. Pirámide de la dieta mediterránea. Disponible en: http://fdmed.org/piramide-dietamediterranea/.
356. Williams PT. Relationship of distance run per week to coronary heart disease risk factors in 8283 male runners. The National Runners’ Health Study. Arch Intern Med. 1997;157(2):191-8.
357. Williams PT. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am J Clin Nutr. 2008;87(5):1480-7.
358. Murphy-Bielicki B, Schumacher HR. How does patient education affect gout? Clin Rheumatol Pract. 1984;2:77-80.
359. Schumacher HR. Patient education: How can we improve it and evaluate the effects? Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2011;17(5):229-30.
360. Terkeltaub R. The management of gout and hyperuricemia. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 5 ed. Philadelphia. 2011. p. 1867-74.
361. Wernick R, Winkler C, Campbell S. Tophi as the initial manifestation of gout. Report of six cases and review of the literature. Arch Intern Med. 1992;152(4):873-6. Epub 1992/04/01.
362. Ferraz MB, O’Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 1995;22(5):908-14. .
363. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Annals of the rheumatic diseases. 2007;66(8):1056-8.
364. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol. 2001;28(3):577-80.
365. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321-5.
366. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2006;12(2):61-5. Epub 2006/04/08.
367. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47(4):356-60.
368. Fathallah N, Ben Salem C, Slim R, Kaabia N, Letaief A, Bouraoui K. Fatal allopurinol-induced hypersensitivity syndrome associated with pancreatic abnormalities. J Clin Rheumatol . 2010;16(4):170-1.
369. Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P, Miguel-De la Villa F. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ. 2005;331(7517):623-4.
370. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25-32.
371. Braden GL, Warzynski MJ, Golightly M, Ballow M. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol. 1994;70(2):145-51.
372. Rozieres A, Vocanson M, Said BB, Nosbaum A, Nicolas JF. Role of T cells in nonimmediate allergic drug reactions. Curr Opin Allergy Clin Immunol. 2009;9(4):305-10.
373. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9(11):1617-22. .
374. Stamp L, Dockerty J, Frampton C, Robinson P, Jones P, Taylor W, et al. Allopurinol starting dose as a risk factor for allopurinol hypersensitivity syndrome in patients with gout Ann Rheum Dis . 2011;70(Suppl3):180.
375. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum. 2001;44(1):231-8.
376. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38(9):1957-9.
377. US Food and Drug Administration. Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). 2011; Disponible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm243770.htm.
378. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711-20.
379. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis . 2008;67(7):960-6.
380. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31(8):1575-81.
381. Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006;55(5):786-90.
382. AEMPS. Alopurinol. Ficha técnica. 2012; Dsiponible en: http://www.aemps.gob.es/cima/especialidad.do?metodo=verFichaWordPdf&codigo=63480&formato=pdf&formulario=FICHAS&file=ficha.pdf.
383. Perez-Ruiz F, Urresola A, Gorostiza D, Canteli B. Validation of the measurement of tophi with magnetic resonance imaging as an outcome measure for chronic gout. Arthitis Rheum 2011;63(10):S77.
384. Yue TF, Gutman AB. Effect of allopurinol (4-hidroxypyrazolo-(3,4-D) pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med. 1964;37:885-98.
385. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623-44.
386. Day RO, Miners JO, Birkett DJ, Whitehead A, Naidoo D, Hayes J, et al. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol. 1988;26(4):423-8.
387. Stamp LK, Barclay ML, O’Donnell JL, Zhang M, Drake J, Frampton C, et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther. 2011;90(3):392-8.
388. Chiou CC, Yang LC, Hung SI, Chang YC, Kuo TT, Ho HC, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol. 2008;22(9):1044-9.
389. Shalom R, Rimbroth S, Rozenman D, Markel A. Allopurinol-induced recurrent DRESS syndrome: pathophysiology and treatment. Ren Fail. 2008;30(3):327-9.
390. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35-44.
391. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18(2):99-107.
392. Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006;46(1):88-102.
393. Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet. 2006;45(8):821-41.
394. Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2008;48(9):1014-24.
395. Becker MA, Schumacher HR, Jr., Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52(3):916-23.
396. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273-82.
397. Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol. 1998;431:13-8.
398. Pascual E, Jovani V. A quantitative study of the phagocytosis of urate crystals in the synovial fluid of asymptomatic joints of patients with gout. Br J Rheumatol. 1995;34(8):724-6.
399. Pascual E, Castellano JA. Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals. J Rheumatol. 1992;19(4):600-3.
400. Yu T. The efficacy of colchicine prophylaxis in articular gout–a reappraisal after 20 years. Semin Arthritis Rheum . 1982;12(2):256-64.
401. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429-32.
402. Beutler AM, Rull M, Schlesinger N, Baker DG, Hoffman BI, Schumacher HR, Jr. Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels. Clin Exp Rheumatol. 2001;19(5):595.
403. Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58(9):2882-91.
404. Sivera F, Andres M, Pascual M. Serum uric acid drops during acute inflammatory episodes. Annals of the rheumatic diseases. 2010;69(Suppl 3):122.
405. Pardo V, Andres M, Caturla JM, Pascual E. Hypouricemia due to high urate renal excretion in septic systemic inflammatory response syndrome. Intensive Care Med. 2011;37(Suppl 1):0152.
406. Bellamy N, Downie WW, Buchanan WW. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol. 1987;24(1):33-6.
407. Schlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol. 2002;29(2):331-4.
408. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs. 2004;64(21):2399-416. Epub 2004/10/16.
409. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout–a systematic review. Rheumatology (Oxford). 2006;45(11):1422-31.
410. García de la Torre I. Estudio doble-ciego paralelo, comparativo con tenoxican vs. placebo en artritis gotosa aguda. Invest Med Int. 1987;14(2):92-7.
411. Rubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 2004;50(2):598-606.
412. Schumacher HR, Jr., Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002;324(7352):1488-92.
413. Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med. 1995;26(6):682-6.
414. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout. Curr Med Res Opin. 1991;12(7):423-9
415. Bori Segura G, Hernandez Cruz B, Gobbo M, Lanas Arbeloa A, Salazar Paramo M, Teran Estrada L, et al. Uso apropiado de los antiinflamatorios no esteroideos en reumatologia: documento de consenso de la Sociedad Espanola de Reumatologia y el Colegio Mexicano de Reumatologia.Reumatol Clin. 2009;5(1):3-12. Epub 2009/02/01..
416. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2000(4):CD002296.
417. Park SC, Chun HJ, Kang CD, Sul D. Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury. World J Gastroenterol. 2011;17(42):4647-53.
418. Loza E. AINEs en la práctica clínica: lo que hay que saber. Inf Ter Sist Nac Salud. 2011;35:88-95.
419. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
420. Fernandez C, Noguera R, Gonzalez JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol. 1999;26(10):2285-6.
421. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49(5):670-7.
422. Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev. 2008(2):CD005521.
423. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371(9627):1854-60.
424. Schlesinger N, Schumacher R, Catton M, Maxwell L. Colchicine for acute gout. Cochrane Database Syst Rev. 2006(4):CD006190.
425. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17(3):301-4.
426. Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine–guidelines for use. J Rheumatol. 1988;15(3):495-9.
427. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007;57(7):1324-8.
428. Hollister AS, Becker MA, Terkeltaub RA, Waugh A, Lyman S, Flynt A, et al. BCX4208 shows synergistic reductions in serum uric acid in gout patients when combined with allopurinol. Ann Rheum Dis. 2011;70 (Suppl 3):183.
429. Fleischmann R, Shen Z, Yeh LT, Kerr B, Polvent E, Suster M, et al. Lesinurad (RDEA594), a novel oral uricosuric agent, in combination with febuxostat shows significant additive urate lowering effects in gout patients with 100% response achieved for all combination dose regimens.Ann Rheum . 2011;170(Suppl 3):188.
430. Yeh LT, Shen Z, Kerr B, Hingorani V, Polvent E, Miner JN, et al. RDEA594, a novel uricosuric agent, shows impressive reductions in serum urate levels as monotherapy and substantial additive activity in combination with febuxostat in normal healthy volunteers.Ann Rheum . 2010;69(Suppl3):611.
431. Goldfarb E, Smyth CJ. Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout. Arthritis Rheum. 1966;9(3):414-23.
432. Perez-Ruiz F, Herrero-Beites AM, Atxotegi J. Uricosuric therapy of hyperuricemia in gout. In: Terkeltaub RA, editor. Gout & Other Crystal Arthropathies. 1 ed. Philadelphia: Elsevier; 2011. p. 148-53.
433. AEMPS. Comité de Seguridad de Medicamentos de Uso Humano. Restricción del uso de benzbromarona (Urinorm®) y suspensión de comercialización de benziodarona (Dilafurane®) y de las asociaciones benzbromarona-alopurinol (Acifugan®, Facilit®). Actual Farmacol Terap. 2004;2(1):43.
434. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens. 2001;19(10):1855-60.
435. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Annals of the rheumatic diseases. 2003;62(6):572-5.
436. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-41.
437. EMA. Anakinra (kineret). 2012; Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000363/WC500042310.pdf.
438. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra’s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum . 2010;40(3):210-4.
439. Moltó A, Ea H-K, Richette P, Bardin T, Lioté F. Efficacy of anakinra for refractory polyarticular gout and acute CPP arthritis Ann Rheum Dis . 2011;70(Suppl3):183.
440. EMA. Canakinumab (Ilaris). 2011;Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/001109/WC500031680.pdf.
441. So A, Alten R, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab versus triamcinolone acetonide in the treatment of acute flares in gouty arthritis in patients contraindicated, intolerant or unresponsive to NSAIDS and/or colchicine. Ann Rheum Dis . 2011;70(Suppl3):183.
442. Schlesinger N, Schumacher HR, Bardin T, Alten R, Bloch M, Brown JP, et al. Efficacy of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients: results of the B-Relieved II study (response in acute flare and in prevention of episodes of re-flare in gout.Ann Rheum Dis . 2011;70(Suppl3):183.
443. EMA. Rilonacept (Arcalyst). 2011;Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/001047/WC500026510.pdf.
444. Terkeltaub R, Schumacher HR, Curtis C, Patterson N, Evans RR, Wang JK. Evaluation of rilonacept in patients with gouty arthritis experiencing an acute gout attack. . Arthritis Rheum. 2010;62(Suppl 10):153.
445. AEMPS. Actualización sobre la evaluación de riesgos de los AINE tradicionales y medidas reguladoras previstas. Nota informativa. 2006;Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2006/docs/NI_2006-07_AINE.pdf.
446. AEMPS. Actualización sobre los riesgos de tipo aterotrombótico de los COXIBS y AINE tradicionales. Nota informativa. 2006;Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2006/docs/NI_2006-10_coxibs_AINE.pdf.
447. AEMPS. Prednisona. Ficha técnica. 2002;Disponible en: https://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFichaWordPdf&codigo=47863&formato=pdf&formulario=FICHAS&file=ficha.pdf.
448. Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum. 2009;61(9):1268-70.
449. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra.Ann Rheum Dis . 2007;66(12):1683-4.
450. Pérez Ruiz F, Atxotegui Sáenz de Buruaga J, López Santamaría R, Herrero Beites AM, de Miguel M, Alonso Ruiz A. Anakinra en dosis bajas es eficaz en la prevención de los episodios agudos de inflamación en pacientes con gota severa. Reumatol Clin. 2012;8(Espec Cong):29-176
451. Evans RR, Terkeltaub RA, Schumacher HR, Saag KG, Weinstein SP, Wang J, et al. Efficacy and safety of rilonacept for prevention of gout flares during initiacion of urate-lowering therapy Ann Rheum Dis . 2011;70(Suppl 3):182.
452. Mitha E, Fouche L, Wang J, Evans RR, Weinstein SP, Schumacher HR. Evaluation of rilonacept for prevention of gout flares during initiation of uric acid-lowering therapy: results of a phase 3, randomized, double-blind, placebo-controlled global trial. Ann Rheum Dis . 2011;70(Suppl 3):168.
453. EMA. Rasburicasa (Fasturtec). 2009;Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000331/WC500021499.pdf.
454. Richette P, Briere C, Hoenen-Clavert V, Loeuille D, Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol. 2007;34(10):2093-8.
455. FDA. Pegloticasa (Krystexxa). 2010;Disponible en: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM227568.pdf.
456. Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 2008;60(1):59-68. Epub 2007/09/11.
457. Becker MA, Baraf HS, Yood RA, Dillon A, Vazquez-Mellado J, Ottery FD, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.Ann Rheum Dis . 2012.
458. Perez-Ruiz F, Sundy J, Krishnan E, Hingorani V, Welp J, Suster M, et al. Efficacy and safety of lesinurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: randomized, double-blind, placebo-controlled, phase 2B study. Ann Rheum Dis . 2010;69(Suppl 3):609.
459. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728-34.
460. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000;39(6):655-65.
461. Perez-Ruiz F, Nolla JM. Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2003;9(4):215-8.
462. Kim KA, Joo HJ, Park JY. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur J Clin Pharmacol. 2011;67(2):129-34.
463. Nakayama A, Matsuo H, Takada T, Ichida K, Nakamura T, Ikebuchi Y, et al. ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1091-7.
464. Perez-Ruiz F, Naredo E. Imaging modalities and monitoring measures of gout. Curr Opin Rheumatol. 2007;19(2):128-33.
465. Bloch C, Hermann G, Yu TF. A radiologic reevaluation of gout: a study of 2,000 patients. AJR Am J Roentgenol. 1980;134(4):781-7.
466. Dalbeth N, Clark B, Gregory K, Gamble GD, Doyle A, McQueen FM. Computed tomography measurement of tophus volume: comparison with physical measurement. Arthritis Rheum. 2007;57(3):461-5.
467. Ottaviani S, Allard A, Bardin T, Richette P. An exploratory ultrasound study of early gout. Clin Exp Rheumatol. 2011;29(5):816-21.
468. Schueller-Weidekamm C, Schueller G, Aringer M, Weber M, Kainberger F. Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol. 2007;62(3):437-43.
469. Filippucci E, Ciapetti A, Grassi W. [Sonographic monitoring of gout]. Reumatismo. 2003;55(3):184-6.
470. Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int. 2010;30(4):495-503.